Anixa Biosciences, Inc.
Anixa Biosciences, Inc. (ANIX) is a small-cap, clinical-stage biotechnology company focused on developing immunotherapies and diagnostic technologies. Investors should know it operates in a high-risk, high-reward segment: progress depends heavily on clinical trial outcomes, regulatory decisions and successful commercialisation of any products. With a market capitalisation of about $137.6m, liquidity and analyst coverage may be limited, which can increase share-price volatility. Key potential value drivers include trial readouts, regulatory milestones, strategic partnerships and diagnostic adoption; conversely, setbacks, funding needs and dilution are common risks for companies at this stage. For those tracking ANIX, review company filings, press releases, clinicaltrials.gov entries and quarterly cash-flow reports to gauge runway and progress. This summary is for general education only, not personalised investment advice. Consider your risk tolerance and diversification needs, and consult a financial professional before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Anixa Biosciences' stock, anticipating it will reach a target price of $7.
Financial Health
Anixa Biosciences is maintaining steady financial performance with consistent cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ANIX
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Trial readouts and regulatory milestones can materially affect valuation — though outcomes are uncertain and setbacks are common.
Technology Focus
Focus on immunotherapies and diagnostics may offer long-term opportunities if programmes succeed, but development and commercial risks remain significant.
Market Dynamics
As a small-cap biotech with ~ $137.6m market cap, ANIX can be volatile and may face liquidity or funding challenges; diversification helps manage risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
